Predictors for high costs of hospital care in elderly hypertensive patients

Blood Pressure

Volumn 15, Issue 4, 2006, Pages 245-250

  Linjer, Erland ^a   Jornmark, Jan ^b   Hedner, Thomas ^a,b   Jonsson, Bengt ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

ACE inhibitors; Calcium antagonists; Cost; Diuretics beta blockers; Elderly; Hospital; Hypertension; Institutional care; Nursing home; STOP Hypertension 2; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; FEMALE; FORECASTING; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERTENSION; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICS; SWEDEN;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; FEMALE; FORECASTING; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYPERTENSION; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; SEX FACTORS; SWEDEN;

EID: 33847172807     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050600912237     Document Type: Article

References (19)

1. SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-3264
2. Dahlö f B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in Old Patients with Hypertension. (STOP-Hypertension). Lancet. 1991;338:1281-1285
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;18:2981-2997
4. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Intern Med. 1995;237:19-26
5. Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990;263:407-413 (Pubitemid 20026015)
6. Nissinen A, Tuomilehto J, Kottke T, Puska P. Costeffectiveness of the North Karelia hypertension program: 1972-1977. Med Care. 1986;24:767-780
7. Jönsson B.Measurement of health outcome and associated costs in cardiovascular disease. Eur Heart J. 1996;17 Suppl A:2-7 (Pubitemid 26129712)
8. 1999 orld Health Organization-International Society of Hypertension, Guidelines for the Management of Hypertension. Blood Press. 1999;8 Suppl 1:9-43
9. Hansson L, Lindholm L H, Ekbom T, Dahlö f B, Lanke J, Scherstén B, Wester P-O, Hedner T, de FaireU for the STOPHypertension-2 study group, Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756
10. Hansson L, Hedner T, Dahlö f B. Prospective Randomised Open Blinded End-point (PROBE) study: A novel design for intervention trials. Blood Press. 1992;1:113-119
11. Lindholm LH, Johannesson M. Cost-benefit aspects of treatment of hypertension in the elderly. Blood Press. 1995;4 Suppl 3:11-14
12. Lindholm LH, Hansson L, Dahlö f B, Ekbom T, Hedner T, De Faire U, et al. The Swedish Trial in old patients with Hypertension-2 (STOP-Hypertension-2) : A progress report. Blood Press. 1996;5:300-304 (Pubitemid 26290694)
13. Linjer E, Hedner T, Jönsson B, Ekbom T, Lindholm L H, Dahlö f B, et al. Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Press. 2005;14:1-7
14. Jönsson B, Hansson L, Stålhammar N-O. Health economics in the Hypertension Optimal Treatment (HOT) study: Costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med. 2003;253:472-480, Moderate hypertension. SBU Report 17 D 2004 (Pubitemid 36418933)
15. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003; 10:1779-1786 (Pubitemid 37290093)
16. Diringer MN, Edwards DF, Mattson DT, Atkins PT, Sheedy CW, Hsu CY, et al. Predictors of acute costs for treatment of ischemic stroke in an academic center. Stroke. 1999;30:724-728 (Pubitemid 29156358)
17. Paul SD, Eagle KA, Guidry U, DiSalvo TG, Villareal-Levy G, Smith C, et al. Do gender-based differences in presentation and management influence predictors of hospitalization costs and length of stay after an acute myocardial infarction? Am J Cardiol. 1995;76:1122-1125
18. Weinstein MC, Stason WB. Allocations or resources to manage hypertension. N Engl J Med. 1977;2967:732-739
19. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, Guidelines Committee. J Hypertens. 2003;21:1011-1053.